896 Shares in CRISPR Therapeutics AG (NASDAQ:CRSP) Bought by Sachetta LLC

Sachetta LLC acquired a new stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 896 shares of the company’s stock, valued at approximately $56,000.

A number of other hedge funds have also recently bought and sold shares of the company. Norges Bank bought a new position in shares of CRISPR Therapeutics during the fourth quarter valued at about $38,661,000. Manchester Capital Management LLC bought a new position in shares of CRISPR Therapeutics during the 4th quarter worth approximately $63,000. Sheaff Brock Investment Advisors LLC purchased a new position in shares of CRISPR Therapeutics in the 4th quarter worth approximately $208,000. Brown Advisory Inc. bought a new position in shares of CRISPR Therapeutics in the fourth quarter valued at approximately $235,000. Finally, Beacon Pointe Advisors LLC purchased a new stake in shares of CRISPR Therapeutics during the fourth quarter valued at approximately $236,000. 69.20% of the stock is owned by hedge funds and other institutional investors.

CRISPR Therapeutics Stock Up 0.2 %

CRSP stock opened at $54.89 on Wednesday. CRISPR Therapeutics AG has a twelve month low of $37.55 and a twelve month high of $91.10. The firm has a market capitalization of $4.66 billion, a PE ratio of -20.13 and a beta of 1.80. The stock has a 50-day simple moving average of $61.27 and a two-hundred day simple moving average of $65.64.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its earnings results on Wednesday, May 8th. The company reported ($1.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.08). The company had revenue of $0.50 million for the quarter, compared to analyst estimates of $25.53 million. During the same quarter in the previous year, the business earned ($0.67) earnings per share. The company’s revenue for the quarter was down 99.5% compared to the same quarter last year. On average, equities research analysts anticipate that CRISPR Therapeutics AG will post -5.64 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. Cantor Fitzgerald restated a “neutral” rating on shares of CRISPR Therapeutics in a research note on Thursday, May 9th. Mizuho increased their price target on shares of CRISPR Therapeutics from $82.00 to $99.00 and gave the company a “buy” rating in a research report on Wednesday, March 6th. JMP Securities reaffirmed a “market outperform” rating and issued a $86.00 price objective on shares of CRISPR Therapeutics in a research report on Thursday, May 9th. Morgan Stanley increased their target price on shares of CRISPR Therapeutics from $46.00 to $48.00 and gave the company an “underweight” rating in a research report on Monday, February 26th. Finally, Wolfe Research assumed coverage on shares of CRISPR Therapeutics in a research note on Thursday, February 15th. They set a “peer perform” rating for the company. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $73.93.

Insider Transactions at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 19,582 shares of CRISPR Therapeutics stock in a transaction on Monday, April 15th. The stock was sold at an average price of $59.91, for a total transaction of $1,173,157.62. Following the completion of the sale, the chief executive officer now owns 208,122 shares of the company’s stock, valued at $12,468,589.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 19,582 shares of the firm’s stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $59.91, for a total value of $1,173,157.62. Following the sale, the chief executive officer now owns 208,122 shares of the company’s stock, valued at approximately $12,468,589.02. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, General Counsel James R. Kasinger sold 2,801 shares of CRISPR Therapeutics stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $78.26, for a total value of $219,206.26. Following the sale, the general counsel now owns 60,070 shares of the company’s stock, valued at approximately $4,701,078.20. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 55,709 shares of company stock valued at $3,865,228. 4.10% of the stock is currently owned by company insiders.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.